Related Experiment Video

Updated: Mar 28, 2026

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation
08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

8.7K

PI3K Inhibitor Improves PFS in BELLE-2 Trial

    Cancer Discovery
    |December 19, 2015
    PubMed

    Abstract:

    Adding a PI3K inhibitor to anti-estrogen receptor therapy may be a viable treatment option for women with advanced hormone receptor-positive breast cancer that becomes resistant to endocrine therapy, according to findings from the phase III BELLE-2 trial, presented at the 2015 San Antonio Breast Cancer Symposium.

    More Related Videos

    Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
    08:45

    Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

    Published on: July 17, 2020

    6.7K
    Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
    10:27

    Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

    Published on: July 25, 2020

    8.1K

    Related Experiment Videos

    Last Updated: Mar 28, 2026

    An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation
    08:48

    An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

    Published on: June 30, 2015

    8.7K
    Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
    08:45

    Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

    Published on: July 17, 2020

    6.7K
    Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
    10:27

    Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

    Published on: July 25, 2020

    8.1K

    Related Concept Videos

    PI3K/mTOR/AKT Signaling Pathway01:22

    PI3K/mTOR/AKT Signaling Pathway

    6.3K
    The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
    6.3K

    Articles linked to this work by shared authors, journal, and citation graph.

    Transmissible Cancer Discovered in Catfish.

    Cancer discovery·2026

    Follicular Lymphoma Transformation is Characterized by Cytokine-associated Remodeling of Stromal and Macrophage Compartments.

    Cancer discovery·2026

    Genomics of Subsequent Neoplasms in Childhood Cancer Survivors.

    Cancer discovery·2026

    A Counterintuitive Approach to Cancer Therapy.

    Cancer discovery·2026

    Rare Fusions, Real Targets: Ultraprecision Oncology in Lung Cancer.

    Cancer discovery·2026

    Lung Tumors Hack Nervous System to Drive Cachexia.

    Cancer discovery·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us